Jeff Yass’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-23,700
| Closed | -$477K | – | 13990 |
|
|
2026
Q1 | $477K | Buy |
+23,700
| New | +$382K | ﹤0.01% | 9799 |
|
|
2024
Q4 | – | Sell |
-12,300
| Closed | -$142K | – | 12737 |
|
|
2024
Q3 | $142K | Sell |
12,300
-4,300
| -26% | -$54.1K | ﹤0.01% | 10791 |
|
|
2024
Q2 | $196K | Sell |
16,600
-25,300
| -60% | -$295K | ﹤0.01% | 10382 |
|
|
2024
Q1 | $497K | Sell |
41,900
-36,000
| -46% | -$480K | ﹤0.01% | 8525 |
|
|
2023
Q4 | $954K | Buy |
77,900
+24,200
| +45% | +$220K | ﹤0.01% | 7102 |
|
|
2023
Q3 | $517K | Sell |
53,700
-52,800
| -50% | -$539K | ﹤0.01% | 8150 |
|
|
2023
Q2 | $959K | Buy |
+106,500
| New | +$982K | ﹤0.01% | 6775 |
|
|
2022
Q1 | – | Sell |
-10,400
| Closed | -$138K | – | 13513 |
|
|
2021
Q4 | $138K | Sell |
10,400
-89,500
| -90% | -$1.42M | ﹤0.01% | 11886 |
|
|
2021
Q3 | $1.74M | Buy |
99,900
+6,800
| +7% | +$138K | ﹤0.01% | 6147 |
|
|
2021
Q2 | $2.23M | Sell |
93,100
-37,500
| -29% | -$981K | ﹤0.01% | 5666 |
|
|
2021
Q1 | $3.35M | Sell |
130,600
-23,100
| -15% | -$607K | ﹤0.01% | 4721 |
|
|
2020
Q4 | $2.92M | Buy |
+153,700
| New | +$2.64M | ﹤0.01% | 4354 |
|
Other funds holding KALV
Jeff Yass's KALV Position: Q2 2026 in Review
Jeff Yass sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 46,760 shares — an estimated $941K sold.
Jeff Yass first reported a position in KALV in Q2 2016 and held it in 24 quarters. The position peaked at $4.79M in Q3 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Jeff Yass reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jeff Yass sold 46,760 KalVista Pharmaceuticals shares in Q2 2026, an estimated $941K.
- Jeff Yass first reported a position in KalVista Pharmaceuticals in Q2 2016 and held it in 24 quarters.
- Jeff Yass's KalVista Pharmaceuticals position peaked at $4.79M in Q3 2025.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.